Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-19T17:38:52.608Z Has data issue: false hasContentIssue false
  • English
  • Français

The current state of infection with respiratory syncytial virus in the setting of congenital cardiac malformations

Published online by Cambridge University Press:  13 October 2006

Timothy F. Feltes ,
Richard L. Hodinka ,
Stephen M. Paridon ,
Gil Wernovsky  and
Henry M. Sondheimer
Timothy F. Feltes
Affiliation:
Division of Pediatric Cardiology, Columbus Children's Hospital and the Ohio State University, Columbus, Ohio, United States of America
Richard L. Hodinka
Affiliation:
Division of Infectious Diseases, Department of Pediatrics and Anatomical Pathology and Laboratory Medicine, Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
Stephen M. Paridon
Affiliation:
Division of Pediatric Cardiology, Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
Gil Wernovsky
Affiliation:
Division of Pediatric Cardiology, Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
Henry M. Sondheimer
Affiliation:
Division of Pediatric Cardiology, The University of Colorado and the Children's Hospital, Denver, Colorado, United States of America
Get access Rights & Permissions [Opens in a new window]

Abstract

A long with prematurity and chronic lung disease, the presence of congenital cardiac disease in infants and young children is a significant risk for the clinical consequences of an illness produced by infection with the respiratory syncytial virus.1 In this review, we present a current understanding of such illnesses, their prevention, and their treatment.

Keywords

Pathophysiologyprophylaxisprevention
Type
Miscellaneous Topics
Information
Cardiology in the Young , Volume 16 , Supplement S3: Controversies and Challenges of the Atrioventricular Junctions and Other Challenges Facing Paediatric Cardiovascular Practitioners and their Patients , September 2006 , pp. 136 - 143
Copyright
© 2006 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffen MR. Rates of hospitalization for respiratory syncytial virus among children in Medicaid. J Pediatr 2000; 137: 865–870.Google Scholar
Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 344: 1917–1928.Google Scholar
Henrickson KJ. Advances in the laboratory diagnosis of viral respiratory disease. Pediatr Infect Dis J 2004; 23: S6–S10.Google Scholar
Hansen T, Corbet A. In: Taeusch HW, Ballard RA (eds). Avery's Diseases of the Newborn. WB Saunders, Philadelphia, 1998, pp 541–667.
Inselman LS, Mellins RB. Growth and development of the lung. J Pediatr 1981; 98: 1–15.Google Scholar
Feltes TF, Hansen TN. Effects of an aorticopulmonary shunt on lung fluid balance in the young lamb. Pediatr Res 1989; 26: 94–97.Google Scholar
Miserocchi G, Negrini D, Passi A, De Luca G. Development of lung edema: interstitial fluid dynamics and molecular structure. News Physiol Sci 2001; 16: 66–71.Google Scholar
Fu Z, Heldt GP, West JB. Increased fragility of pulmonary capillaries in newborn rabbit. Am J Physiol Lung Cell Mol Physiol 2003; 284: L703–L709.Google Scholar
Matthay MA, Folkesson HG, Clerici C. Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev 2002; 82: 569–600.Google Scholar
Drake R, Giesler M, Laine G, Gabel J, Hansen T. Effect of outflow pressure on lung lymph flow in unanesthetized sheep. J Appl Physiol 1985; 58: 70–76.Google Scholar
Johnson SA, Vander Straten MC, Parellada JA, Schnakenberg W, Gest AL. Thoracic duct function in fetal, newborn, and adult sheep. Lymphology 1996; 29: 50–56.Google Scholar
Carpenter TC, Stenmark KR. Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis. Pediatr Infect Dis J 2004; 23(Suppl): S33–S40.Google Scholar
Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000; 161: 1501–1507.Google Scholar
Piedimonte G. Contribution of neuroimmune mechanisms to airway inflammation and remodeling during and after respiratory syncytial virus infection. Pediatr Infect Dis J 2003; 22 (Suppl): S66–S74; discussion S74–S75.Google Scholar
MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory Syncytial virus infection in infants with congenital heart disease. N Engl J Med 1982; 307: 397–400.Google Scholar
Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidimeol 1969; 89: 435–448.Google Scholar
Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and children. N Engl J Med 1993; 329: 1524–1530.Google Scholar
Simoes EA, Sondheimer HM, Top Jr FH, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory Syncytial virus disease in infants and children with congenital heart disease. J Pediatr 1998; 133: 492–499.Google Scholar
Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalizations from respiratory syncytial virus infections. Pediatrics 1998; 102: 531–537.
Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532–540.Google Scholar
Kneyber MCJ, Moons KGM, deGroot R, Moli HA. Prediction of duration of hospitalization in respiratory syncytial virus infection. Pediatr Pulmon 2002; 33: 453–457.Google Scholar
Buckingham SC, Quasney MW, Bush AJ, DeVincenzo JP. Respiratory syncytial virus infections in the pediatric intensive care unit: clinical characteristics and risk factors for adverse outcomes. Pediatr Crit Care Med 2001; 2: 318–323.Google Scholar
Panitch HB. Bronchiolitis in infants. Curr Opin Pediatr 2001; 13: 256–260.Google Scholar
Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Resp Care 2003; 48: 209–230.Google Scholar
McKinley G, Ballard J, Salyer J. The effect of NP suctioning on symptom scores in bronchiolitis patients (abstract). Respir Care 2001; 47: 1071.Google Scholar
Barr FE, Patel NR, Newth CJ. The pharmacologic mechanism by which inhaled epinephrine reduces airway obstruction in respiratory syncytial virus-associated bronchiolitis. J Pediatr 2000; 136: 699–700.Google Scholar
Garrison MM, Christakis DA, Harvey E, Cummings P, Davis RL. Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatr 2000; 105: E44.Google Scholar
Jafri HS. Treatment of respiratory syncytial virus: antiviral therapies. Pediatr Inf Dis J 2003; 22: S89–SS93.Google Scholar
Hall CB, McBride JT, Gala CL, Hildreth SW, Schnabel KC. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA 1985; 254: 3047–3051.Google Scholar
Meert KL, Sarnik AP, Gelmini MJU, Lieh-lei MW. Aerosolized ribiviran treatment in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double blind, randomized trial. Crit.Care Med 1994: 22: 566–572.Google Scholar
Law BJ, Wang EE, Mac Donald N, et al. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection: an analysis using the pediatric investigators collaborative network on infections in Canada (PIC-NIC) RSV database. Pediatr 1997; 99: e7.Google Scholar
Groothuis JR, Woodin KA, Katz R, et al. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr 1990; 117: 792–798.Google Scholar
Malley R, Devincenzo J, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998; 178: 1555–1561.Google Scholar
Saez-Llorens X, Moreno MT, Ramilo O, et al. Phase I/II, double-blind, placebo-controlled, multidose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (MEDI-493) in children hospitalized with RSV (Abstract 906). Presented at the Society for Pediatric Research, New Orleans, May 1 to 5, 1998: 156A.
Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of Palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatr 2003; 112: 1442–1446.